| |
September 14, 2023 | 1:00 PM ET Over 50% of life sciences companies are doing patient finding. Are you? Register now to learn about patient finding best practices, use cases and common pitfalls. AIML is here. Be ready with Trinity Life Sciences. .png)
|
|
Today’s Big NewsAug 21, 2023 |
| By Annalee Armstrong Exactly a month after Gilead revealed it had shelved a myelodysplastic syndromes program for magrolimab, the molecule has been placed under a partial clinical hold by the FDA for its phase 3 acute myeloid leukemia studies. |
|
|
|
| Philadelphia, PA |  |
|
|
By James Waldron What could be hotter than Moderna getting in the Claudin18.2 race? How about pairing up this mRNA therapeutic cancer vaccine with a solid tumor-targeting CAR-T? |
By Gabrielle Masson Layoffs in the biotech industry for 2023 have matched the total number of companies that cut staff in all of 2022, with 119 biopharmas reporting workforce reductions so far this year, according to an analysis of Fierce Biotech data. |
By James Waldron Hutchmed is gearing up to submit sovleplenib for approval in the company’s native China after the Syk inhibitor scored a phase 3 win. |
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now. 
|
|
By Helen Floersh Researchers have, for the first time, reconstructed a tune from a person’s brain activity as they listened to a song, a feat that marks a major milestone in scientists’ ability to decode and understand how the brain perceives music. It could eventually make assistive voice technologies and speech prosthetics better at replicating human speech by improving their prosody. |
By Fraiser Kansteiner Roche’s immuno-oncology star Tecentriq plus Exelixis and Ipsen’s tyrosine kinase inhibitor Cabometyx helped patients with pretreated metastatic castration-resistant prostate cancer live longer without their disease getting worse, the partners said Monday. In turn, the combo therapy hit one of two primary endpoints in the phase 3 CONTACT-02 trial. |
By Conor Hale First spun out of Stanford University in late 2019, the company's deep learning platform helps design small-molecule drug compounds and predicts how they interact with the body. |
By Kevin Dunleavy With the FDA signing off on Regeneron and Bayer’s high-dose Eylea, the companies are set to take on Roche’s Vabysmo in a high-stakes battle for the massive eye disease market. |
By Paige Minemyer It's not a secret that Americans pay far more than people living in other countries for drugs, and those data hold for trendy weight loss and diabetes treatments like Ozempic and Wegovy. |
By Sam Whitehead, Kaiser Health News Failure to make sweeping changes could add to a growing lack of trust in the agency post-pandemic and threaten the nation’s preparedness for the next public health threat. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we take a closer look at the challenges with new email policies, and the importance of diverse investors and founders. |
|
|---|
|
|
|
October 16-17 | Boston, MA Effectively drive collaboration between R&D, clinical and commercial teams to develop an appropriate timeline and practical approach to bringing new products to launch. Book you seat today and save $200! |
|
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
